{"disease":{"id":"locally-advanced-pancreas-cancer","name":"locally advanced pancreas cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06714604","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT05975593","title":"MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT02404363","title":"Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07157033","title":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Xerient Pharma","has_results":false},{"nct_id":"NCT07457541","title":"Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Tomsk National Research Medical Center of the Russian Academy of Sciences","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}